Articles tagged with Alzheimer Disease
Researchers at Université de Montréal discovered that recalling celebrity faces decreases with age, but accessing biographical knowledge via their name remains unaffected. This semantic memory test could become a crucial tool to identify individuals at risk of developing Alzheimer's disease.
A diet rich in methionine, found in red meats and fish, may increase the risk of developing Alzheimer's disease by accelerating amyloid plaque formation. Research suggests that high levels of homocysteine, a byproduct of methionine breakdown, can lead to increased dementia risk.
Researchers identify ineffective communication strategies that can worsen problem behaviors in family members with dementia. Effective communication, on the other hand, can resolve misunderstandings and reduce distress. The study aims to develop empirically derived communication interventions for caregivers targeting both problems.
Researchers from Boston University School of Medicine found that higher leptin levels are associated with a lower incidence of Alzheimer's Disease and dementia. The study suggests that leptin may have beneficial effects on brain development and function, potentially opening pathways for preventive and therapeutic interventions.
Two new studies suggest that late-life dementia is a complex disease resulting from multiple processes, including Alzheimer's disease, vascular brain injury, and Lewy body disease. Higher levels of leptin may also be linked to reduced risk of Alzheimer's disease, according to the findings.
A study found that individuals with higher leptin levels had a reduced incidence of Alzheimer's disease and dementia. Higher leptin levels were also associated with increased total cerebral brain volume.
A new study published in JAMA found that tarenflurbil, a drug intended to reduce amyloid-β levels, showed no benefit in slowing cognitive decline or improving daily activities in patients with mild Alzheimer's disease. The researchers concluded that interventions targeting amyloid have not yet been shown to alter the course of AD.
A new imaging test has detected early Alzheimer's disease in older adults, which is likely to progress into symptomatic Alzheimer's disease. The test uses Pittsburgh Compound B (PiB) to bind to beta-amyloid plaques in the brain, identifying individuals who are at risk of developing dementia.
Researchers at Washington University found brain plaques in healthy individuals are associated with increased risk of Alzheimer's diagnosis years later. Annual cognitive tests and MRI scans revealed declining scores, shrinkage in affected brain areas, and eventual diagnosis.
Researchers at the Salk Institute found that slowing aging in mice with Alzheimer's-like symptoms prevented brain damage and impaired cognitive function. The study suggests that modulating the IGF-1 signaling pathway can have a protective effect against Alzheimer's disease.
Researchers have created human stem cell-derived neurons to model Alzheimer's disease and Niemann-Pick Type C, revealing early transport defects as a key factor in severe neuronal dysfunction. The study aims to understand how genetic differences affect cellular transport and behavior in these diseases.
New research suggests HIV-related cognitive deficits share a common link with Alzheimer's-related dementia: low levels of the protein amyloid beta in spinal fluid. This study can help find the cause of cognitive impairment in HIV patients and may impact new Alzheimer's treatments.
Scientists at Boston Biomedical Research Institute discovered that combining EGCG and DAPH-12 can prevent and destroy various protein structures known as amyloids, which are primary culprits in fatal brain disorders. The study may contribute to future therapies for Alzheimer's, Huntington's, and Parkinson's diseases.
Researchers at Gladstone Institute of Neurological Disease have discovered that two main causes of AD, amyloid-beta peptides and apolipoprotein E4, impair the growth of new neurons born in adult brains. Drug treatments can normalize their development even in the presence of these factors.
Researchers at Tel Aviv University found that amyloid-beta is necessary for normal day-to-day information transfer through nerve cell networks in the brain. The study suggests that removing amyloid-beta may impair neuronal function and accelerate Alzheimer's disease progression.
Researchers at Washington University School of Medicine studied 575 patients who underwent surgery and found no evidence of long-term cognitive decline. The study suggests that if older adults physically recover from surgery, they will return to their previous level of cognitive ability within six months or a year.
Researchers found that a lower-calorie diet slows development of age-related conditions such as Alzheimer's disease, while a high-calorie diet accelerates oxidative stress. Dietary restriction activates transcription factor CBP, which regulates cellular function.
The study utilizes a viral-based gene transfer system to make Nerve Growth Factor (NGF), which helps maintain nerve cell survival in the brain. Participants will receive CERE-110 via neurosurgery or placebo surgery and undergo thorough medical examinations and cognitive testing.
The ACT study focuses on finding ways to delay or prevent dementia, including Alzheimer's disease. Recent findings highlight the role of vascular disease and controlling high blood pressure in reducing the risk of late-life dementia.
Researchers developed a fast and accurate method to quantify subtle brain volume loss in Alzheimer's patients, outperforming existing measures. The new technique identifies changes in memory regions, particularly the entorhinal cortex, as sensitive markers for early disease stages.
A new study reveals a novel mouse gene that reduces Alzheimer's disease pathologies by interacting with a key cellular enzyme. The research found that the gene, Rps23r1, interacts with glycogen synthase kinase-3 (GSK-3) and inhibits its activity, resulting in improved AD-like pathologies in transgenic mice.
A new mouse gene, Rps23r1, has been identified as a potential therapeutic target for reducing amyloid beta and tau levels in the brain. The gene triggers a signaling pathway that inhibits GSK-3, regulating protein generation and tangle formation. This finding offers new hope for treating Alzheimer's disease.
Researchers found that low doses of amyloid beta protein improved learning and memory in healthy mice, while blocking the protein caused learning impairment. The study suggests that the optimal amount of amyloid beta is crucial for maintaining cognitive function.
Researchers found that taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen can prevent the early sign of Alzheimer's disease in mice. However, these same drugs do not reverse existing neuronal cell cycle events in affected animals.
A study of 970 older adults found that those with weaker muscles were more likely to develop Alzheimer's disease and experience cognitive decline. Muscle strength was also linked to the development of mild cognitive impairment, suggesting a common pathogenesis underlying loss of muscle strength and cognition in aging.
Researchers at the University of Michigan have developed hybrid molecules that can regulate copper-induced amyloid-beta aggregation, disrupting clump formation and breaking up existing clumps. The new compounds also hold promise in treating Alzheimer's disease and may be able to cross the blood-brain barrier.
Research suggests that high blood pressure and inflammatory markers are more prevalent in middle age among individuals with a family history of Alzheimer's disease. The study also found that these risk factors cluster within families, highlighting the potential for early interventions to prevent late-onset Alzheimer's disease.
Research published in Neurology suggests that people with both diabetes and Alzheimer's disease have a slower rate of memory loss than those with only Alzheimer's. The study found that diabetes may actually counteract the progression of cognitive decline in Alzheimer's patients, although the reasons for this effect are still unclear.
Studies suggest ophthalmologists should suspect visual variant Alzheimer's in patients with unusual or severe vision problems, particularly difficulty reading. Nearsighted individuals may be less susceptible to diabetic retinopathy due to reduced risks associated with longer axial length and deeper anterior eye chamber.
Researchers at Mayo Clinic found that inflammation in the brain helps clear amyloid deposits, contradicting long-standing scientific belief. The study suggests that manipulating brain inflammation could be a potential therapeutic approach to treat Alzheimer's disease.
Researchers have discovered that Alzheimer's disease can cause changes in the retina, which may predict how well treatments will work. The findings could lead to the development of retinal imaging technology for earlier diagnosis and treatment of Alzheimer's, a leading cause of elderly dementia.
Research from the American Journal of Pathology reveals that glycosaminoglycans contribute to skeletal abnormalities in patients with lysosomal storage diseases. Additionally, αvβ3-integrin expression improves ovarian cancer patient prognosis, while CpG DNA may be a therapeutic candidate for Alzheimer's disease treatment.
Researchers found that a high protein diet led to smaller brains in mice with Alzheimer's disease. The study suggests a possible link between high protein intake and reduced AD risk.
Research at Georgetown University Medical Center found that APP plays a critical role in brain development, connection of synapses, and dendritic spine development. Overproducing APP can lead to Abeta plaques and cognitive decline, highlighting the importance of maintaining balance in APP protein expression.
Researchers discover that activating brain immune cells with IL-6 leads to clearance of amyloid plaques, suggesting a new therapeutic approach for Alzheimer's disease. This breakthrough discovery may lead to a treatment that removes these hallmark disease-causing structures from patients' brains.
Researchers found that declines in visuospatial skills and cognitive abilities can occur years before clinical diagnosis of Alzheimer's disease. These findings suggest that conventional methods for diagnosing the disease may not be sensitive to early manifestations of the condition.
Researchers at UT Southwestern Medical Center found that applying a second brain protein, Reelin, can prevent excess beta-amyloid from silencing nerves and potentially fighting Alzheimer's disease. The study suggests a promising new tactic against the devastating illness.
A new study has found that older people taking cholinesterase-inhibiting drugs like donepezil are more likely to be hospitalized for bradycardia, an abnormally slow resting heart rate. This condition can cause serious symptoms such as fainting and shortness of breath.
Researchers will explore epigenetic changes and their relationship with memory formation, cognitive decline, and Alzheimer's disease. The studies aim to understand how life experiences contribute to the biological changes of Alzheimer's and may lead to therapeutic interventions.
Researchers at the Monell Chemical Senses Center discovered that oleocanthal alters the structure of neurotoxic beta-amyloid proteins, impairing their ability to damage brain nerve cells. This structural change makes oleocanthal a potential target for developing effective immunotherapy treatments.
Researchers at USF Health found that inhibiting the chaperone protein Hsp70 can reduce brain levels of toxic tau protein associated with Alzheimer's disease. The study suggests that targeting Hsp70 could lead to more effective treatments for Alzheimer's and other neurodegenerative diseases.
Dr. Roger Rosenberg has been awarded the first Medal for Scientific Achievement by the World Federation of Neurology for his contributions to Alzheimer's disease research. The award recognizes his work on molecular genetics and a vaccine against the disease.
The GAP study investigates the safety and effectiveness of IGIV in patients with mild to moderate AD, aiming to slow disease progression. Initial research suggests that IGIV may neutralize toxic forms of beta amyloid, promoting its elimination.
Researchers found that chronic sleep deprivation accelerates amyloid plaque deposition in mice with Alzheimer's disease. Orexin, a protein regulating the sleep cycle, appears directly involved in this process.
Researchers are conducting a phase II gene therapy trial using CERE-110 to treat patients with mild Alzheimer's disease. The study aims to determine the safety and benefits of injecting the gene into the brain, which produces Nerve Growth Factor to help nerve cells survive.
A new study from UAB researchers suggests that individuals with mild cognitive impairment (MCI) who struggle with financial management skills may be at risk for developing Alzheimer's disease. The study found that MCI patients who declined in financial capacity over a year were more likely to progress to Alzheimer's.
A team of researchers led by Dr. Alon Monsonego has created a humanized mouse model that responds specifically to an A-beta-peptide vaccine, reducing plaque and inflammation in the brain. The study provides a basis for developing individualized immunotherapeutic approaches to Alzheimer's disease.
Researchers discovered a link between declining financial skills and the development of Alzheimer's disease. Participants with mild cognitive impairment (MCI) who showed poorer money management abilities were more likely to progress to dementia.
The Rosalinde and Arthur Gilbert Foundation awards $75,000 grants to five early-career scientists studying the earliest brain changes suggesting Alzheimer's disease. The recipients aim to accelerate development of diagnostic, preventative interventions, and treatments.
A study published in Archives of Neurology found that those with more difficulties performing daily activities are at increased risk for progressing quickly to dementia. Functional impairment at baseline was the only factor associated with conversion from mild cognitive impairment to dementia.
A study found that people with infections were more likely to experience memory loss and cognitive decline compared to those without infections. The study suggests that reducing inflammation may be beneficial for people with Alzheimer's disease.
Researchers at Columbia University Medical Center found that a cancer drug can restore memory deficits in patients with Alzheimer's disease by targeting a previously unknown defect in the brain. The drug works by increasing DNA spool acetylation and gene transcription, leading to improved memory performance.
A $1.1 million grant from CIHR will support John MacDonald's research on preventing nerve cell death in Alzheimer's and stroke. The study aims to develop a peptide that can prevent toxic interactions between ion channels, which may lead to breakthroughs in treatment.
A team of international scientists has identified two more genetic risk factors for Alzheimer's disease, which appear to be involved in elevated risk and confirmed the importance of APOE4. The new genes, APOJ and PICALM, are linked to smaller but still significant effects on Alzheimer's disease risk.
British scientists have discovered two new genes associated with Alzheimer's disease, CLU and PICALM. These findings provide valuable new leads in the race to find treatments and possibly cures for the common form of Alzheimer's disease.
Researchers at Duke University Medical Center have made a breakthrough in understanding how monkeys weigh costs and benefits when deciding whether to explore new options or stick with what they know. By analyzing neural signals in the posterior cingulate cortex, the team was able to predict which strategy the monkey would employ.
Researchers discovered that the N60 section of the RanBP9 protein increases amyloid beta production in Alzheimer's disease brains. Targeting this fragment may lead to novel strategies to combat Alzheimer's disease.
A team of researchers led by UIC's Mary Jo LaDu will examine the biology of apolipoprotein E and its receptors in the central nervous system. The $10M grant aims to understand the progression of Alzheimer's disease.
Researchers from UCLA and Pittsburgh found that obese individuals have a 8% less brain tissue than those with normal weight, while overweight individuals have 4% less tissue. This increased risk is linked to severe brain degeneration and cognitive decline.
A study mapping brain activity networks in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) patients reveals distinct changes in communication between brain areas. AD patients show more random network organization, while FTLD patients display a more ordered structure, challenging the understanding of these diseases.